Structure Therapeutics Inc. (Nasdaq:GPCR)
Health Care/Life Sciences • Biotechnology
CIK 1888886
Company
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company engaged in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in San Francisco, CA.
Address
611 Gateway Boulevard
Suite 223
San Francisco, California 94080
611 Gateway Boulevard
Suite 223
San Francisco, California 94080
Employees
68
68
Stock Info
Key Executives
Board Of Directors
Chairman Daniel G Welch MBA |
Chief Executive Officer & Director Raymond C Stevens PhD |
Chief Financial Officer & Director Jun Yoon |
Director Eric Hands Claude Bjerkholt MBA |
Independent Director Sharon E Tetlow MBA |
Independent Director Ramy Farid PhD |
Independent Director Cui Ping Gu PhD |
Independent Director Jessica Lifton |
Independent Director Chen-Ming Yu MD, MBA |
Independent Director Ted W Love MD |
Independent Director Eric L Dobmeier |
Independent Director Joanne Waldstreicher MD |
SEC filings
Date | Form | Event |
---|---|---|
17 Dec, 2024 | 8-K | |
14 Nov, 2024 | SC 13G/A | |
14 Nov, 2024 | SC 13G/A | |
14 Nov, 2024 | SC 13G | |
13 Nov, 2024 | 10-Q | |
13 Nov, 2024 | 8-K | |
12 Nov, 2024 | SC 13G | |
12 Nov, 2024 | SC 13G/A | |
8 Nov, 2024 | SC 13G/A | |
20 Sep, 2024 | 3 | |
20 Sep, 2024 | 4 | |
20 Sep, 2024 | 4 | |
20 Sep, 2024 | 3 | |
17 Sep, 2024 | 8-K | |
28 Aug, 2024 | 4 | |
28 Aug, 2024 | 3 | |
27 Aug, 2024 | 8-K | |
8 Aug, 2024 | 10-Q | |
8 Aug, 2024 | 8-K | |
27 Jun, 2024 | 4 | |
27 Jun, 2024 | 8-K | |
27 Jun, 2024 | 4 | |
27 Jun, 2024 | 4 | |
27 Jun, 2024 | 4 | |
27 Jun, 2024 | 4 | |
14 Jun, 2024 | 4 | |
13 Jun, 2024 | 3 | |
12 Jun, 2024 | 4 | |
10 Jun, 2024 | 144 | |
6 Jun, 2024 | 424B4 | |
5 Jun, 2024 | S-1MEF | |
5 Jun, 2024 | EFFECT | |
5 Jun, 2024 | 4 | |
4 Jun, 2024 | UPLOAD | |
3 Jun, 2024 | 8-K | |
3 Jun, 2024 | CORRESP | |
3 Jun, 2024 | 144 | |
3 Jun, 2024 | S-1 | |
3 Jun, 2024 | CORRESP | |
3 Jun, 2024 | 8-K | |
31 May, 2024 | CORRESP | |
31 May, 2024 | UPLOAD | |
30 May, 2024 | SC 13G | |
24 May, 2024 | CORRESP | |
22 May, 2024 | UPLOAD | |
9 May, 2024 | 8-K | |
9 May, 2024 | 10-Q | |
25 Apr, 2024 | ARS | |
25 Apr, 2024 | DEF 14A | |
19 Apr, 2024 | 4 | |
20 Mar, 2024 | 4/A | |
20 Mar, 2024 | 4/A | |
20 Mar, 2024 | 4/A | |
20 Mar, 2024 | 4/A | |
20 Mar, 2024 | 4/A | |
19 Mar, 2024 | 4 | |
19 Mar, 2024 | 4 | |
19 Mar, 2024 | 4 | |
19 Mar, 2024 | 4 | |
19 Mar, 2024 | 4 | |
18 Mar, 2024 | 4 | |
8 Mar, 2024 | 8-K | |
8 Mar, 2024 | 10-K | |
8 Mar, 2024 | S-8 | |
15 Feb, 2024 | 4 | |
14 Feb, 2024 | SC 13G/A | |
14 Feb, 2024 | SC 13G | |
9 Feb, 2024 | SC 13G/A | |
9 Feb, 2024 | SC 13G/A | |
8 Feb, 2024 | SC 13G | |
6 Feb, 2024 | SC 13G/A | |
27 Dec, 2023 | 4 | |
20 Dec, 2023 | SC 13G/A | |
18 Dec, 2023 | 8-K | |
7 Dec, 2023 | 4 | |
29 Nov, 2023 | EFFECT | |
27 Nov, 2023 | CORRESP | |
24 Nov, 2023 | UPLOAD | |
24 Nov, 2023 | UPLOAD | |
20 Nov, 2023 | DRS | |
17 Nov, 2023 | S-1 | |
17 Nov, 2023 | 10-Q/A | |
17 Nov, 2023 | 10-Q | |
16 Nov, 2023 | 10-Q/A | |
14 Nov, 2023 | 8-K | |
14 Nov, 2023 | NT 10-Q | |
23 Oct, 2023 | 4 | |
13 Oct, 2023 | SC 13G/A | |
12 Oct, 2023 | 3 | |
4 Oct, 2023 | SC 13G/A | |
29 Sep, 2023 | 8-K | |
29 Sep, 2023 | 8-K | |
10 Aug, 2023 | 8-K | |
10 Aug, 2023 | 10-Q | |
4 Aug, 2023 | 4 | |
4 Aug, 2023 | 3 | |
4 Aug, 2023 | 8-K | |
4 Aug, 2023 | 4 | |
6 Jul, 2023 | 8-K | |
5 Jun, 2023 | 8-K | |
12 May, 2023 | 4 | |
11 May, 2023 | 10-Q | |
11 May, 2023 | 8-K | |
30 Mar, 2023 | 10-K | |
30 Mar, 2023 | 8-K | |
13 Feb, 2023 | 3 | |
13 Feb, 2023 | SC 13G | |
10 Feb, 2023 | SC 13G | |
10 Feb, 2023 | SC 13G | |
9 Feb, 2023 | 4 | |
9 Feb, 2023 | 4 | |
9 Feb, 2023 | 4 | |
9 Feb, 2023 | 4 | |
9 Feb, 2023 | 4 | |
9 Feb, 2023 | 4 | |
9 Feb, 2023 | 4 | |
9 Feb, 2023 | 4 | |
7 Feb, 2023 | 8-K | |
6 Feb, 2023 | 424B4 | IPO completed |
6 Feb, 2023 | 4 | |
6 Feb, 2023 | 4 | |
6 Feb, 2023 | S-8 | |
3 Feb, 2023 | SEC STAFF | |
3 Feb, 2023 | SC 13G | |
2 Feb, 2023 | EFFECT | |
2 Feb, 2023 | 3 | |
2 Feb, 2023 | 3 | |
2 Feb, 2023 | 3 | |
2 Feb, 2023 | 3 | |
2 Feb, 2023 | 3 | |
2 Feb, 2023 | 3 | |
2 Feb, 2023 | 3 | |
2 Feb, 2023 | CERT | |
2 Feb, 2023 | S-1MEF | |
2 Feb, 2023 | 3 | |
2 Feb, 2023 | 3 | |
2 Feb, 2023 | 3 | |
2 Feb, 2023 | 3 | |
2 Feb, 2023 | 3 | |
2 Feb, 2023 | 3 | |
2 Feb, 2023 | EFFECT | |
31 Jan, 2023 | CORRESP | |
31 Jan, 2023 | CORRESP | |
30 Jan, 2023 | 8-A12B | |
30 Jan, 2023 | S-1/A | |
30 Jan, 2023 | F-6 | |
23 Jan, 2023 | CORRESP | |
12 Jan, 2023 | CORRESP | |
12 Jan, 2023 | S-1 | |
4 Jan, 2023 | UPLOAD | |
6 Dec, 2022 | DRS/A | |
5 Dec, 2022 | DRSLTR | |
27 May, 2022 | UPLOAD | |
13 May, 2022 | DRS/A | |
12 May, 2022 | DRSLTR | |
16 Mar, 2022 | SEC STAFF | |
14 Mar, 2022 | UPLOAD | |
14 Feb, 2022 | DRS | |
10 Jan, 2022 | D | |
21 Oct, 2021 | D | |
21 Oct, 2021 | D | |
21 Oct, 2021 | D |
Last update:2024-03-06 12:38:12.992155
Sign Up to Subscribe
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.